Medtronic (NYSE: MDT) today announced that it received CE mark approval for its SenSight directional lead system for deep brain stimulation therapy.
SenSight works seamlessly with certain Medtronic neurostimulators including the Percept PC neurostimulator. It enhances the detection of local field potentials and has directional stimulation for individualized and patient-specific data with additional programming features to personalize therapy.
“This is the only directional lead with built-in sensing capabilities,” Jens Volkmann, chairman and professor of neurology in the University Clinic of Würzburg, said in a news release. “The challenge of DBS is to provide stimulation to a very small brain region only at times, when fluctuating symptoms require treatment. This new technology holds promise for a truly personalized therapy, which we can adapt using the objective data from each patient to inform programming in ‘space and time.’”
SenSight directional leads were first implanted at the University Clinic of Würzburg and Grenoble Alpes University Hospital on March 17 and March 18. The company plans to fully launch in Western Europe following the CE mark approval.
“Medtronic has been driving innovation in DBS therapy for more than 25 years and the approval of the SenSight directional lead system in the EU is our latest contribution to the quest for improved patient experiences and clinical outcomes,” Mike Daly, VP and GM of brain modulation in Medtronic’s neuromodulation business, said. “Our commitment to evolving DBS therapy is unwavering and we look forward to introducing additional advancements in 2021 and beyond.”
Medtronic’s SenSight is currently under review by the FDA in the U.S.